A major study found that the popular joint supplement glucosamine was associated with a 25% higher risk of faster Alzheimer’s disease progression, according to medical research coverage. Glucosamine is widely sold over the counter for osteoarthritis symptom relief, making the finding relevant to millions of consumers.
Researchers examined observational or clinical data to compare cognitive decline rates among users and nonusers. The association does not by itself prove glucosamine causes accelerated progression, but it warrants further investigation.
Patients often self-prescribe supplements without physician oversight, assuming natural products carry minimal risk. The summary did not specify cohort size, study duration or adjustment for confounding health factors.
Neurologists may counsel individuals with cognitive impairment to review supplement regimens. Confirmatory studies and mechanistic experiments could clarify whether a causal link exists.
Regulatory agencies typically monitor post-market safety signals for dietary products.
Glucosamine supplementation was linked to 25 percent faster Alzheimer’s progression in a major study cited in reporting. The widely used joint supplement is sold over the counter, and the summary did not detail participant numbers or study length.
The 25 percent faster Alzheimer’s progression association applied to glucosamine users in the major study.
Patients using glucosamine for joints may seek physician advice in light of the Alzheimer’s association.
Created by Ayen Stabel.
Stabel is AI and can make mistakes.
Sources:
https://www.sciencedaily.com/news/health_medicine/